Silvergate Pharmaceuticals releases Xatmep Oral Solution
DENVER — Silvergate Pharmaceuticals Inc. has launched Xatmep Oral Solution (methotrexate 2.5 mg/ml), a medication used for leukemia and arthritis in children. Silvergate said Xatmep is the first and only Food and Drug Administration-approved methotrexate oral solution and will be available via an extensive network of pharmacies. Xatmep is indicated for the treatment of acute
